Skip to main content
Top
Published in: Journal of Cardiothoracic Surgery 1/2023

Open Access 01-12-2023 | Spinal Muscular Atrophy | Case Report

Surgical correction of a ventricular septal defect in a child with spinal muscular atrophy type 2 treated with nusinersen sodium: a case report

Authors: Mehmet Biçer, Şima Kozan, Figen Öztürk, Ayfer Arduç Akçay

Published in: Journal of Cardiothoracic Surgery | Issue 1/2023

Login to get access

Abstract

Introduction

Spinal muscular atrophy (SMA) is a severe, inherited neuromuscular disorder characterized by progressive muscle weakness and atrophy. Cardiac pathology co-existence is reported more frequently in the severely affected patient groups. Structural heart anomalies, mainly septal, and outflow tract defects are commonly observed pathologies.

Case presentation

We herein report the case of a 23 days-old female patient with the diagnosis of spinal muscular atrophy type 2 complicated with structural heart defects. Successful pulmonary banding, and at the age of 17 months, subsequent surgical atrial and ventricular septal defect closure were performed on our patient who was under treatment of Nusinersen Sodium. Post-operative recovery was uncomplicated. Cardiac assessments were normal, and the patient was neurologically improving in her recent follow-up.

Conclusion

In the literature, there are no reported cases of successful surgical repair of heart defects in spinal muscular atrophy patients. These patients can be perceived as risky surgical candidates with suboptimal postoperative recovery given the unfavorable disease prognosis of SMA in untreated patients. We report our promising experience with a SMA type 2 patient undergoing a disease-modifying medical treatment. The SMA patients under treatment may be potential candidates for successful surgical cardiac correction given their overall improved prognosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723–32.CrossRefPubMed Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723–32.CrossRefPubMed
3.
go back to reference Wijngaarde CA, Blank AC, Stam M, Wadman RI, van den Berg LH, van der Pol WL. Cardiac pathology in spinal muscular atrophy: a systematic review. Orphanet J Rare Dis. 2017;12(1):67.CrossRefPubMedPubMedCentral Wijngaarde CA, Blank AC, Stam M, Wadman RI, van den Berg LH, van der Pol WL. Cardiac pathology in spinal muscular atrophy: a systematic review. Orphanet J Rare Dis. 2017;12(1):67.CrossRefPubMedPubMedCentral
4.
go back to reference Djordjevic SA, Milic-Rasic V, Brankovic V, Kosac A, Vukomanovic G, Topalovic M, et al. Cardiac findings in pediatric patients with spinal muscular atrophy types 2 and 3. Muscle Nerve. 2021;63(1):75–83.CrossRefPubMed Djordjevic SA, Milic-Rasic V, Brankovic V, Kosac A, Vukomanovic G, Topalovic M, et al. Cardiac findings in pediatric patients with spinal muscular atrophy types 2 and 3. Muscle Nerve. 2021;63(1):75–83.CrossRefPubMed
5.
go back to reference Formigari R, Michielon G, Digilio MC, Piacentini G, Carotti A, Giardini A, et al. Genetic syndromes and congenital heart defects: how is surgical management affected? Eur J Cardiothorac Surg. 2009;35(4):606–14.CrossRefPubMed Formigari R, Michielon G, Digilio MC, Piacentini G, Carotti A, Giardini A, et al. Genetic syndromes and congenital heart defects: how is surgical management affected? Eur J Cardiothorac Surg. 2009;35(4):606–14.CrossRefPubMed
6.
go back to reference Ramsey D, Scoto M, Mayhew A, Main M, Mazzone ES, Montes J, et al. Revised Hammersmith Scale for spinal muscular atrophy: a SMA specific clinical outcome assessment tool. PLoS ONE. 2017;12(2): e0172346.CrossRefPubMedPubMedCentral Ramsey D, Scoto M, Mayhew A, Main M, Mazzone ES, Montes J, et al. Revised Hammersmith Scale for spinal muscular atrophy: a SMA specific clinical outcome assessment tool. PLoS ONE. 2017;12(2): e0172346.CrossRefPubMedPubMedCentral
7.
go back to reference Graham RJ, Athiraman U, Laubach AE, Sethna NF. Anesthesia and perioperative medical management of children with spinal muscular atrophy. Paediatr Anaesth. 2009;19(11):1054–63.CrossRefPubMed Graham RJ, Athiraman U, Laubach AE, Sethna NF. Anesthesia and perioperative medical management of children with spinal muscular atrophy. Paediatr Anaesth. 2009;19(11):1054–63.CrossRefPubMed
8.
go back to reference De Vivo DC, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842–56.CrossRefPubMedPubMedCentral De Vivo DC, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842–56.CrossRefPubMedPubMedCentral
9.
go back to reference Glascock J, Sampson J, Haidet-Phillips A, Connolly A, Darras B, Day J, et al. Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening. J Neuromuscul Dis. 2018;5(2):145–58.CrossRefPubMedPubMedCentral Glascock J, Sampson J, Haidet-Phillips A, Connolly A, Darras B, Day J, et al. Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening. J Neuromuscul Dis. 2018;5(2):145–58.CrossRefPubMedPubMedCentral
10.
go back to reference Dangouloff T, Botty C, Beaudart C, Servais L, Hiligsmann M. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J Rare Dis. 2021;16(1):47.CrossRefPubMedPubMedCentral Dangouloff T, Botty C, Beaudart C, Servais L, Hiligsmann M. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J Rare Dis. 2021;16(1):47.CrossRefPubMedPubMedCentral
11.
go back to reference Michelson D, Ciafaloni E, Ashwal S, Lewis E, Narayanaswami P, Oskoui M, et al. Evidence in focus: Nusinersen use in spinal muscular atrophy: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2018;91(20):923–33.CrossRefPubMed Michelson D, Ciafaloni E, Ashwal S, Lewis E, Narayanaswami P, Oskoui M, et al. Evidence in focus: Nusinersen use in spinal muscular atrophy: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2018;91(20):923–33.CrossRefPubMed
Metadata
Title
Surgical correction of a ventricular septal defect in a child with spinal muscular atrophy type 2 treated with nusinersen sodium: a case report
Authors
Mehmet Biçer
Şima Kozan
Figen Öztürk
Ayfer Arduç Akçay
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Journal of Cardiothoracic Surgery / Issue 1/2023
Electronic ISSN: 1749-8090
DOI
https://doi.org/10.1186/s13019-023-02170-z

Other articles of this Issue 1/2023

Journal of Cardiothoracic Surgery 1/2023 Go to the issue